Seaport Therapeutics Stock
Seaport Therapeutics, Inc. Common Stock
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Daphne Zohar
- Employees
- 58
- Market cap
- $954 M
- IPO
- 01/05/2026
Seaport Therapeutics, Inc. is a developing biopharmaceutical enterprise currently undergoing clinical trials, focused on creating groundbreaking treatments for neuropsychiatric conditions. The company is primarily engaged in tackling disorders like depression and anxiety, utilizing its unique Glyph technology. This…
Seaport Therapeutics stock: price history
1D
+1.3%
1W
-1.8%
1M
-19.5%
6M
–
YTD
–
1Y
–
2Y
–
5Y
–
10Y
–
Next earnings date
Next earnings date
02/11/2026 (in 16 days)
Volatility around earnings
Not enough history for an assessment
Ask the agents about Seaport Therapeutics
Analyst assessment of Seaport Therapeutics
PRICE TARGET LOW
US$28.00
CONSENSUS
US$38.50
MEDIAN
US$38.00
PRICE TARGET HIGH
US$50.00
0
STRONG BUY
1
BUY
0
HOLD
0
SELL
0
STRONG SELL
1
TOTAL · Buy
As of: 08/10/2026
Seaport Therapeutics stock metrics
P/E
-10.81
P/B
2.26
EV/EBITDA
-9.66
RETURN ON EQUITY
-14.8%
NET MARGIN
0.0%
DEBT/EQUITY
0.01
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
34.4%
FLOAT SHARES
18,434,316
AVG. DAILY VOLUME (30D)
274,311
Insider transactions (SEC)
HOMBACH ROBERT J.
PureTech Health plc
PureTech Health plc
PureTech Health plc
Loebel Antony
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: +1.3%
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about Seaport Therapeutics stock
What does Seaport Therapeutics do?
Seaport Therapeutics, Inc. Common Stock is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Daphne Zohar, the company employs around 58 people.
The IPO was on 01/05/2026; the stock trades on NASDAQ under the ticker SPTX.
What do analysts say about Seaport Therapeutics stock?
1 analysts rate the stock, the consensus is Buy (as of 08/10/2026).
The average price target is US$38.50, ranging from US$28.00 to US$50.00, with a median of US$38.00.
This is an external assessment, not a statement by Market Jury.
When does Seaport Therapeutics report next?
The next earnings date is 02/11/2026.
Does Seaport Therapeutics pay a dividend?
No, Seaport Therapeutics currently does not pay a dividend.
Which stocks are comparable to Seaport Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Seaport Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Seaport Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.